Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in
different ways. Some block the ability of cancer cells to grow and spread. Others find cancer
cells and help kill them or carry cancer-killing substances to them. Giving pentostatin
together with cyclophosphamide and rituximab may kill more cancer cells.
PURPOSE: This phase II trial is studying the side effects and how well giving pentostatin
together with cyclophosphamide and rituximab works in treating patients with previously
untreated chronic lymphocytic leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. National Cancer Institute (NCI)